SG10201913618WA - Use of stem cells to reduce leukocyte extravasation - Google Patents

Use of stem cells to reduce leukocyte extravasation

Info

Publication number
SG10201913618WA
SG10201913618WA SG10201913618WA SG10201913618WA SG10201913618WA SG 10201913618W A SG10201913618W A SG 10201913618WA SG 10201913618W A SG10201913618W A SG 10201913618WA SG 10201913618W A SG10201913618W A SG 10201913618WA SG 10201913618W A SG10201913618W A SG 10201913618WA
Authority
SG
Singapore
Prior art keywords
stem cells
leukocyte extravasation
reduce leukocyte
reduce
extravasation
Prior art date
Application number
SG10201913618WA
Inventor
Hof Wouter Van't
Original Assignee
Abt Holding Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abt Holding Co filed Critical Abt Holding Co
Publication of SG10201913618WA publication Critical patent/SG10201913618WA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48Reproductive organs
    • A61K35/54Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0634Cells from the blood or the immune system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0607Non-embryonic pluripotent stem cells, e.g. MASC
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5073Stem cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00Coculture with; Conditioned medium produced by
    • C12N2502/03Coculture with; Conditioned medium produced by non-embryonic pluripotent stem cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00Coculture with; Conditioned medium produced by
    • C12N2502/11Coculture with; Conditioned medium produced by blood or immune system cells
SG10201913618WA 2009-07-21 2010-07-21 Use of stem cells to reduce leukocyte extravasation SG10201913618WA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US22731109P 2009-07-21 2009-07-21

Publications (1)

Publication Number Publication Date
SG10201913618WA true SG10201913618WA (en) 2020-03-30

Family

ID=43497498

Family Applications (3)

Application Number Title Priority Date Filing Date
SG2012004164A SG178065A1 (en) 2009-07-21 2010-07-21 Use of stem cells to reduce leukocyte extravasation
SG10201404281YA SG10201404281YA (en) 2009-07-21 2010-07-21 Use of stem cells to reduce leukocyte extravasation
SG10201913618WA SG10201913618WA (en) 2009-07-21 2010-07-21 Use of stem cells to reduce leukocyte extravasation

Family Applications Before (2)

Application Number Title Priority Date Filing Date
SG2012004164A SG178065A1 (en) 2009-07-21 2010-07-21 Use of stem cells to reduce leukocyte extravasation
SG10201404281YA SG10201404281YA (en) 2009-07-21 2010-07-21 Use of stem cells to reduce leukocyte extravasation

Country Status (9)

Country Link
US (2) US20110020292A1 (en)
EP (1) EP2456860B1 (en)
AU (1) AU2010276264B2 (en)
CA (1) CA2768573C (en)
DK (1) DK2456860T3 (en)
ES (1) ES2690199T3 (en)
IL (1) IL217643B (en)
SG (3) SG178065A1 (en)
WO (1) WO2011011477A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7015037B1 (en) 1999-08-05 2006-03-21 Regents Of The University Of Minnesota Multiponent adult stem cells and methods for isolation
CN101978047A (en) 2008-01-18 2011-02-16 明尼苏达大学董事会 Stem cell aggregates and methods for making and using
SG10201913920PA (en) 2010-05-12 2020-03-30 Abt Holding Co Modulation of splenocytes in cell therapy
EP3795159A1 (en) 2013-04-12 2021-03-24 Houston Methodist Hospital Improving organs for transplantation
KR20180102661A (en) 2016-01-21 2018-09-17 에이비티 홀딩 컴퍼니 Stem cells for wound healing
KR102548560B1 (en) * 2016-05-20 2023-06-29 로버트 색스테인 Glycoengineering of e-selectin ligands
JP2023523583A (en) * 2020-04-23 2023-06-06 エービーティー ホールディング カンパニー Treatment of virus-induced acute respiratory distress syndrome

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
AU650616B2 (en) 1988-09-21 1994-06-30 Animal Biotechnology Cambridge Limited Derivation of pluripotential embryonic cell lines from domestic animals
US7037721B1 (en) 1990-01-29 2006-05-02 Hy-Gene Biomedical, Inc. Protein-free defined media for the growth of normal human keratinocytes
US5486359A (en) * 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
US5811094A (en) 1990-11-16 1998-09-22 Osiris Therapeutics, Inc. Connective tissue regeneration using human mesenchymal stem cell preparations
US5837539A (en) 1990-11-16 1998-11-17 Osiris Therapeutics, Inc. Monoclonal antibodies for human mesenchymal stem cells
GB2254289B (en) 1991-04-05 1995-03-22 Gerber Garment Technology Inc Readily transferrable adherent tape and methods of use and making
AU2882992A (en) 1991-11-06 1993-06-07 Arthur A. Axelrad Cell culture medium
US5340740A (en) 1992-05-15 1994-08-23 North Carolina State University Method of producing an avian embryonic stem cell culture and the avian embryonic stem cell culture produced by the process
WO1994000484A1 (en) * 1992-06-22 1994-01-06 Young Henry E Scar inhibitory factor and use thereof
US5453357A (en) 1992-10-08 1995-09-26 Vanderbilt University Pluripotential embryonic stem cells and methods of making same
US7153684B1 (en) 1992-10-08 2006-12-26 Vanderbilt University Pluripotential embryonic stem cells and methods of making same
US5766951A (en) 1992-11-12 1998-06-16 Quality Biological, Inc. Serum-free medium supporting growth and proliferation of normal bone marrow cells
US6037174A (en) 1993-08-23 2000-03-14 Nexell Therapeutics, Inc. Preparation of serum-free suspensions of human hematopoietic cells or precursor cells
US5409813A (en) 1993-09-30 1995-04-25 Systemix, Inc. Method for mammalian cell separation from a mixture of cell populations
US6432711B1 (en) 1993-11-03 2002-08-13 Diacrin, Inc. Embryonic stem cells capable of differentiating into desired cell lines
FR2726003B1 (en) 1994-10-21 2002-10-18 Agronomique Inst Nat Rech CULTURE MEDIUM OF AVIAN TOTIPOTENT EMBRYONIC CELLS, METHOD FOR CULTURING THESE CELLS, AND AVIAN TOTIPOTENT EMBRYONIC CELLS
US5914268A (en) 1994-11-21 1999-06-22 National Jewish Center For Immunology & Respiratory Medicine Embryonic cell populations and methods to isolate such populations
US5874301A (en) 1994-11-21 1999-02-23 National Jewish Center For Immunology And Respiratory Medicine Embryonic cell populations and methods to isolate such populations
US5843780A (en) 1995-01-20 1998-12-01 Wisconsin Alumni Research Foundation Primate embryonic stem cells
US5736396A (en) 1995-01-24 1998-04-07 Case Western Reserve University Lineage-directed induction of human mesenchymal stem cell differentiation
GB9502022D0 (en) * 1995-02-02 1995-03-22 Abuljadayel Ilham M S A method for preparing lymphohaematopoietic progenitor cells
US5906934A (en) * 1995-03-14 1999-05-25 Morphogen Pharmaceuticals, Inc. Mesenchymal stem cells for cartilage repair
US6653134B2 (en) * 1995-03-28 2003-11-25 Cp Hahnemann University Isolated stromal cells for use in the treatment of diseases of the central nervous system
US5837670A (en) 1995-04-18 1998-11-17 Hartshorn; Richard Timothy Detergent compositions having suds suppressing properties
US5908782A (en) 1995-06-05 1999-06-01 Osiris Therapeutics, Inc. Chemically defined medium for human mesenchymal stem cells
EP0888377B1 (en) * 1996-03-08 2007-12-12 The Regents Of The University Of Michigan MURINE alpha(1,3)-FUCOSYLTRANSFERASE (Fuc-TVII)
US6190910B1 (en) 1996-05-21 2001-02-20 The Institute Of Physical And Chemical Research Mouse embryonic stem cell lines
US5753506A (en) 1996-05-23 1998-05-19 Cns Stem Cell Technology, Inc. Isolation propagation and directed differentiation of stem cells from embryonic and adult central nervous system of mammals
US5827740A (en) 1996-07-30 1998-10-27 Osiris Therapeutics, Inc. Adipogenic differentiation of human mesenchymal stem cells
US5945337A (en) 1996-10-18 1999-08-31 Quality Biological, Inc. Method for culturing CD34+ cells in a serum-free medium
US6361996B1 (en) 1997-05-07 2002-03-26 University Of Utah Research Foundation Neuroepithelial stem cells and glial-restricted intermediate precursors
AU7984498A (en) 1997-06-25 1999-01-04 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Serum-free cell growth medium
WO1999001159A1 (en) 1997-07-04 1999-01-14 University Of Utah Research Foundation Lineage-restricted neuronal precursors
US5968829A (en) 1997-09-05 1999-10-19 Cytotherapeutics, Inc. Human CNS neural stem cells
US6875607B1 (en) 1998-11-09 2005-04-05 Es Cell International Pte Ltd Embryonic stem cells
WO2000027996A1 (en) 1998-11-09 2000-05-18 Consorzio Per La Gestione Del Centro Di Biotecnologie Avanzate Serum free medium for chondrocyte-like cells
US20050153442A1 (en) 1999-03-10 2005-07-14 Adam Katz Adipose-derived stem cells and lattices
US6777231B1 (en) * 1999-03-10 2004-08-17 The Regents Of The University Of California Adipose-derived stem cells and lattices
US20050169896A1 (en) * 1999-05-14 2005-08-04 Henry Ford Health System Bone marrow transplantation for treatment of stroke
NZ517002A (en) * 1999-08-05 2004-06-25 Mcl Llc Multipotent adult stem cells and methods for isolation
US7015037B1 (en) * 1999-08-05 2006-03-21 Regents Of The University Of Minnesota Multiponent adult stem cells and methods for isolation
US8147824B2 (en) * 1999-08-05 2012-04-03 Athersys, Inc. Immunomodulatory properties of multipotent adult progenitor cells and uses thereof
AU7611500A (en) * 1999-09-24 2001-04-24 Abt Holding Company Pluripotent embryonic-like stem cells, compositions, methods and uses thereof
DE60041821D1 (en) * 1999-09-24 2009-04-30 Cybios Llc PLURIPOTENT EMBRYONAL STEM CELL-SIMILAR CELLS, COMPOSITIONS, AND ITS CONDITIONS
US20030161817A1 (en) * 2001-03-28 2003-08-28 Young Henry E. Pluripotent embryonic-like stem cells, compositions, methods and uses thereof
EP1257282A4 (en) * 1999-12-06 2003-05-02 Gen Hospital Corp Pancreatic stem cells and their use in transplantation
AU3869501A (en) * 2000-02-26 2001-09-03 Artecel Sciences Inc Pleuripotent stem cells generated from adipose tissue-derived stromal cells and uses thereof
US7582292B2 (en) * 2000-02-26 2009-09-01 Artecel, Inc. Adipose tissue derived stromal cells for the treatment of neurological disorders
EP2298867A3 (en) 2000-06-20 2013-01-16 ES Cell International Pte Ltd. Method of controlling differentiation of embryonic stem (ES) cells by culturing ES cells in the presence of bmp-2 pathway antagonists
AU2001284695A1 (en) * 2000-07-31 2002-02-13 New York Medical College Methods and compositions for the repair and/or regeneration of damaged myocardium
AU2001296705A1 (en) * 2000-10-06 2002-04-15 The Regents Of The University Of California Blocking inflammation by inhibiting sialylation
US7560280B2 (en) 2000-11-03 2009-07-14 Kourion Therapeutics Gmbh Human cord blood derived unrestricted somatic stem cells (USSC)
US7311905B2 (en) * 2002-02-13 2007-12-25 Anthrogenesis Corporation Embryonic-like stem cells derived from post-partum mammalian placenta, and uses and methods of treatment using said cells
EP2305795B1 (en) * 2000-12-06 2019-07-03 Celularity, Inc. Method of collecting placental stem cells
EP1491093B1 (en) 2001-02-14 2013-07-31 ABT Holding Company Multipotent adult stem cells, sources thereof, methods of obtaining and maintaining same, methods of differentiation thereof, methods of use thereof and cells derived thereof
EP2336300B1 (en) * 2001-02-14 2015-07-08 Anthrogenesis Corporation Post-partum mammalian placenta, its use and placental stem cells therefrom
US7056738B2 (en) * 2001-03-23 2006-06-06 Tulane University Early stage multipotential stem cells in colonies of bone marrow stromal cells
KR100449141B1 (en) * 2001-04-19 2004-09-21 (주)라이프코드 Method for differentiating a mesenchymal stem cell into neural cells
US20030003090A1 (en) * 2001-05-31 2003-01-02 Prockop Darwin J. Directed in vitro differentiation of marrow stromal cells into neural cell progenitors
BR0212098A (en) 2001-08-23 2004-08-03 Reliance Life Sciences Pvt Ltd Internal cell mass isolation method for the establishment of human embryonic stem cell lines (hesc)
US9969980B2 (en) 2001-09-21 2018-05-15 Garnet Biotherapeutics Cell populations which co-express CD49c and CD90
US6703279B2 (en) 2002-01-04 2004-03-09 Promos Technologies, Inc. Semiconductor device having contact of Si-Ge combined with cobalt silicide
JP2005515777A (en) 2002-01-25 2005-06-02 ジェンザイム・コーポレーション Serum-free medium for chondrocytes and use thereof
US7145057B2 (en) 2002-02-01 2006-12-05 Origen Therapeutics, Inc. Chimeric bird from embryonic stem cells
WO2003080197A1 (en) 2002-03-20 2003-10-02 Sara Griffin Sports training device
GB0221481D0 (en) 2002-09-16 2002-10-23 Richards John M Grip for hand held instruments
US7785601B2 (en) * 2002-12-31 2010-08-31 Sygnis Bioscience Gmbh & Co. Kg Methods of treating neurological conditions with hematopoietic growth factors
US20040235165A1 (en) * 2003-05-19 2004-11-25 Darwin Prockop In vitro differentiation of adult stem cells
WO2005041944A2 (en) * 2003-06-27 2005-05-12 Schepens Eye Research Institute Methods and compositions for promoting axon regeneration and cell replacement therapy
MXPA06000974A (en) * 2003-07-25 2006-08-31 Amgen Inc Antagonists and agonists of ldcam and methods of use.
EP1660644A1 (en) * 2003-08-29 2006-05-31 Regents Of The University Of Minnesota Kidney derived stem cells and methods for their isolation, differentiation and use
US20070225251A1 (en) * 2003-09-08 2007-09-27 Michal Eisenbach-Schwartz Method for Treating or Inhibiting the Effects of Injuries or Diseases that Result in Neuronal Degeneration
US7622108B2 (en) * 2004-04-23 2009-11-24 Bioe, Inc. Multi-lineage progenitor cells
US20100008890A1 (en) * 2006-01-23 2010-01-14 Athersys, Inc. MAPC Therapeutics Without Adjunctive Immunosuppressive Treatment
WO2009043159A1 (en) * 2007-10-01 2009-04-09 The Hospital For Sick Children Neural tumor stem cells and methods of use thereof
US20090130092A1 (en) * 2007-10-30 2009-05-21 Pinsky David J Nucleotide phosphate dissipation as a treatment for vascular disorders

Also Published As

Publication number Publication date
AU2010276264B2 (en) 2013-09-19
EP2456860A4 (en) 2013-08-28
DK2456860T3 (en) 2019-01-07
US20110020292A1 (en) 2011-01-27
SG178065A1 (en) 2012-03-29
US20140134137A1 (en) 2014-05-15
CA2768573A1 (en) 2011-01-27
WO2011011477A1 (en) 2011-01-27
ES2690199T3 (en) 2018-11-19
IL217643B (en) 2018-03-29
SG10201404281YA (en) 2014-09-26
CA2768573C (en) 2020-09-15
EP2456860B1 (en) 2018-09-05
EP2456860A1 (en) 2012-05-30
AU2010276264A1 (en) 2012-03-01

Similar Documents

Publication Publication Date Title
IL217648B (en) Use of stem cells to reduce leukocyte extravasation
GB201213868D0 (en) Improvements in or relating to methods of manufacture
GB201202848D0 (en) Differemtiaiotn of human embryonic stem cells
IL223527B (en) Generation of induced pluripotent stem cells from small volumes of peripheral blood
PL2494832T3 (en) Scheduling of direct to direct communication
GB0902324D0 (en) Improvements relating to valves
IL218996A0 (en) Manipulation of osmolality for differentiating stem cells
GB201015271D0 (en) Improvements relating to wheelchairs
SG10201404281YA (en) Use of stem cells to reduce leukocyte extravasation
PL2411027T3 (en) Use of a probiotic to regulate body weight
GB201011991D0 (en) Improvements relating to valves
HRP20160818T1 (en) Improvements to mechano-chemical reactors
GB0905189D0 (en) Improvements relating to crutches
IL211567A0 (en) Use of stem cells to prevent neuronal dieback
EP2383337A4 (en) Novel promoter for use in transformation of algae
KR101027722B9 (en) Purifier which is able to clean itself
EP2748329A4 (en) Niche targeting of quiescent cancer stem cells
EP2654801A4 (en) Targeting glioma stem cells by sequence-specific functional inhibition of pro-survival oncomir-138
HU0900810D0 (en) Equipment to reduce gas consumption
GB201211721D0 (en) Improvements is or relating to urolgical catheters
TWM370970U (en) Improved structure of working table body
TWM372415U (en) Improved structure of valve sets
PL390098A1 (en) Use of essential oil to control mites
PL390096A1 (en) Use of essential oil to control mites
GB201011738D0 (en) Further improvements to chair arrangement